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PrognosisAbstract Background: The high prevalence of colorectal carcinoma (CRC) is a driver to under-
stand the underlying molecular mechanisms. Chemoprevention strategy using non-steroidal anti-
inﬂammatory drugs (NSAIDs) revealed that these drugs suppress colorectal carcinoma. The best
known targets of NSAIDs are cyclooxygenase (COX) enzymes. The function of prostaglandins
and cyclooxygenase in cancer pathogenesis is unclear. COX-2 regulation of proliferation, apoptosis,
and tumor-blood vessel interaction has been suggested. b-Catenin is a component of the WNT
(wingless type) signaling pathway, increased protein concentrations promote transcription of genes
important in regulating the cell cycle.
Aim: To determine the signiﬁcance of COX-2 and b-catenin expression in colorectal carcinogenesis
and prognosis.
Patients and methods: Thirty patients with colorectal carcinomas treated by colonic resection were
studied for the expression of both COX-2 and b-catenin by immunohistochemistry. Their expres-
sion was interpreted in relation to adjacent normal colonic mucosa and analyzed in correlation with
various clinicopathologic parameters and patient’s survival after a follow up period of 24 months.
Results: Our results showed that in normal adjacent colonic mucosa, COX-2 was completely
absent, whereas b-catenin was speciﬁcally located in the plasma membranes. Both proteins were
expressed in tumorous tissues, COX-2 showed diffuse cytoplasmic positivity, whereas b-catenin
accumulated in both the cytoplasm and nuclei. We established statistically signiﬁcant relationships
between pathological grade and both b-catenin, and COX-2 positivity scores, being at the higher
end for poorly-differentiated tumors. b-Catenin expression also correlated signiﬁcantly with
higher tumor stage and LN metastasis. Both COX-2 and b-catenin expression correlated with a
higher incidence of shorter disease free survival.
212 A. Kazem et al.Conclusion: Both b-catenin and COX-2 expression may play an important role in the evolution of
colon carcinogenesis. Increased expression of both could be used as a marker of tumor progression
and poor prognosis. This might be of therapeutic value for allocating patients with colorectal car-
cinoma to different treatment modalities.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Adenocarcinoma of the colon and rectum is the second leading
cause of death from cancer in the industrialized world.1 In
Egypt, Colorectal carcinoma is the third most common tumor
in males after urinary bladder and lymphohemopoietic malig-
nancies, and in females it ranks ﬁfth after breast, lymphohe-
mopoietic, cervical, and urinary bladder cancers.2 Recently
interest in Egyptian CRC has been raised when clinical studies
revealed a high incidence of the disease among the young
Egyptian population.3 Occurrence of colorectal carcinoma at
young age in Egypt could reﬂect the presence of clinically
inapparent inherited syndromes, furthermore there is a high
prevalence of consanguinity in Egypt because of the tradition
of interfamilial marriages and this cultural characteristic could
contribute to non-syndromic inherited predisposition.4
Several epidemiological researches reported a 40–50% de-
crease in the relative risk of colorectal cancer in persons chron-
ically using non-steroidal anti-inﬂammatory drugs (NSAIDs)
indicating that these drugs might have a chemoprotective
and possibly chemotherapeutic effect.5–9 The best known tar-
gets of NSAIDs are cyclooxygenase (COX) enzymes, which
convert arachidonic acid to prostaglandins (PGs) and throm-
boxane. Among these PGs, prostaglandin E2 (PGE2) can pro-
mote tumor growth by binding its receptors and activating
signal pathways which control cell proliferation, migration,
apoptosis, and angiogenesis. Therefore, COX inhibition is a
promising approach for chemoprevention of colorectal
cancer.10 Unlike COX-1, which is found constitutively in tis-
sues, COX-2 expression is induced by a variety of mediators,
including among others b-catenin.11
b-Catenin plays an important role in the WNT signaling
pathway. Mutations in Wnt/adenomatous polyposis coli
(APC)/b-catenin (CTNNB1) signaling pathway members have
been found in many colorectal carcinomas.12 Wnt ligands bind
to transmembrane Frizzled receptors and their co-receptors,
leading to phosphorylation and sequestration of the complex
composed of APC, casein kinase 1, glycogen synthase kinase
3, and axin. The resultant stabilization of intracellular
CTNNB1 facilitates its translocation to the nucleus, where it
interacts with transcription factors of the T-cell factor/lym-
phoid enhancer-binding factor, activating the targets control-
ling cell growth and differentiation. Therefore, the
interaction with CTNNB1 has been considered to be essential
for the tumor suppressor activity of APC.13 In addition,
CTNNB1 is a multifunctional signaling protein, which also
binds to E-cadherin, linking E-cadherin to actin ﬁlaments
and promoting cell adhesion and differentiation and epithelial
membrane transition (EMT).14 Down-regulation of the
epithelial molecule E-cadherin, is a critical event in tumor
invasion and a master programer of EMT. The molecules in-
volved in EMT represent potential targets for pharmacologicalagents and open new avenues for the control of metastatic
spread in the treatment of malignancies.15
There is increasing evidence that COX-2 and b-catenin are
often co-expressed in cancer cells.16 However, this coordinated
over-expression and its role in colorectal carcinoma needs fur-
ther investigations.
The present study was undertaken on 30 cases of colorectal
carcinoma. The expression and cellular localization of both
COX-2 and b-catenin using immunohistochemistry was
performed to determine the correlation between them and their
relation to various clinicopathological parameters and
patient’s survival after a follow up period of 24 months.
2. Patients and methods
2.1. Patients
The current study was carried out on a total of thirty patients
with colorectal cancer admitted to the department of surgery,
Medical Research Institute, Alexandria University from
February 2009 to February 2012. The patients were 21 male
and 9 female with a male/female ratio of 2.33:1 and a mean
age of 52 years (range, 32–70 years).
Thirteen patients had right colon cancer (5 patients had can-
cer coecum and 8 patients had ascending colon cancer) and 17
patients had left colon cancer (7 patients had descending colon
cancer, 7 patients had sigmoid cancer and 3 patients had recto-
sigmoid cancer). None of the patients had received neoadjuvant
therapy prior to surgery and none had a known family history of
colorectal cancer. All patients included in this study underwent
routine laboratory investigations, radiological investigations
(Barium enema, C.T. abdomen) as well as colonoscopic exami-
nation and biopsy to conﬁrm malignancy. The surgical proce-
dures performed to our patients were right hemicolectomy for
patients with right sided colon cancer, left hemicolectomy
for patients with left sided colon cancer and anterior resection
for patients with sigmoid and rectosigmoid cancer.
After surgery, all patients were referred to cancer manage-
ment and research department for adjuvant treatment which
was given based on the pathological stage and different risk
factors and were followed up for 24 months at the Oncology
unit, while their corresponding colectomy specimens were
examined at the Pathology department; all departments are
afﬁliated to the Medical Research Institute, Alexandria
University, Egypt.
2.2. Methods
In the pathology department, formalin-ﬁxed, parafﬁn-embed-
ded paired tissue sections from colon carcinoma and adjacent
non-malignant mucosa were obtained from each case.
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under a light microscope and the histological type of colorectal
cancer was determined according to the World Health Organi-
zation criteria.17
Tumors were classiﬁed into well, moderately and poorly
differentiated tumors (>50% solid areas) and the T classiﬁca-
tion based on the criteria of classiﬁcation of the American
Joint Committee on Cancer (AJCC).18 was performed.
According to the AJCC classiﬁcation, T1 (tumor has invaded
the lamina propria or muscle layer), T2 (tumor has invaded
the perimuscular connective tissue; no extension beyond the
serosa or into the liver), T3 (tumor has perforated the serosa
or has directly invaded one adjacent organ or both) T4 (tumor
extends more than 2 cm into the liver, and/or into two or more
adjacent organs), respectively.
Respective tissue blocks were then sectioned at 4 lm and
mounted on glass slides coated with 3-aminopropyltrime-
thoxysilane and stained immunohistochemically.2.2.1. Primary antibodies
Two primary antibodies were used; anti-COX-2 rabbit poly-
clonal antibody (Thermo Scientiﬁc, Fermont, USA), used at
a 1:50 dilution and anti- b-catenin rabbit monoclonal antibody
(clone E247; Thermo Scientiﬁc, Fermont, USA), used at a 1:20
dilution.
2.2.2. Immunohistochemistry19
Prior to immunohistochemical staining, sections were depa-
rafﬁnized and rehydrated using standard procedures. Antigen
retrieval was performed using heat treatment; endogenous per-
oxidase activity was blocked by incubation with 3% hydrogen
peroxide for 10 min. To block non-speciﬁc antigen sites, tissue
sections were incubated for 1 h in 1.5% bovine serum albumin
at room temperature. Incubation with the primary antibodies
was performed at room temperature for 30 min with anti-
COX-2 and anti- b-catenin. After the primary antibody incu-
bation step, a secondary antibody from a streptavidin biotin
complex peroxidase kit (LSAB+ kit, Dako, Copenhagen,
Denmark) was used according to the manufacturer’s instruc-
tions. Peroxidase activity was developed with the substrate
3,30-diaminobenzidine tetrahydrochloride (DAB; Dako) by
incubating the sections in DAB for 10 min. Sections were then
rinsed gently with distilled water and counterstained with
hematoxylin.
Appropriate positive and negative controls were included in
each run of immunohistochemistry. Negative controls were
prepared simultaneously for all 30 samples by replacing the
primary antibody with distilled water. Positive staining
controls for COX-2 included sections of lung carcinoma. For
b-catenin normal colonic epithelial cells served as internal
positive controls with membrane staining. External positive
control was sections from breast carcinoma.
2.2.3. Immunohistochemical scoring
Processed specimens were scored under the light microscope.
A method taking into consideration both intensity and
distribution of COX-2 immunoreactivity was employed.20,21
The distribution was scored according to the number of posi-
tive cells; none (not stained), 0; focal (<1/3 of cells stained), 1;
multi-focal (1/3–2/3 of cells stained), 2; and diffuse (>2/3stained), 3. The staining intensity was scored as: none (not
stained), 0; mild (between 0 and 2), 1; and strong, 2. The dis-
tribution and intensity scored were added to produce the fol-
lowing grades for the staining: 0, negative; 2–3 weakly
positive; and 4–5, strongly positive.
As previously described by Jass et al.,22 scoring of b-catenin
was based upon the distribution of b-catenin within the cell
membrane (0–1), cytoplasm (0–2), and nuclei (0–2). We also
calculated b-catenin activation score as the sum of nuclear
score (+2 = positive expression; +1 = weak expression;
0 = no expression), cytoplasmic score (+2 = positive expres-
sion; +1 = weak expression; 0 = no expression), and mem-
brane score (0 = positive membrane expression; +1 =
negative membrane expression). Total scores were then col-
lapsed into three grades (grade I, 0–1; grade II, 2–3; grade
III, 4–5). with a total score of 0 reﬂecting cell membrane stain-
ing only, similar to that seen in normal colonic mucosa, up to
an aggregate score of 5 for tumors with strong nuclear staining
(2), diffuse cytoplasmic staining (2), and loss of cell membrane
staining (1).
2.2.4. Statistical analysis23
Statistical analysis was performed using SPSS for Windows
version 10.0 (SPSS Inc, Chicago, IL, USA).
The relation between COX-2 and b-catenin immunohisto-
chemical scores and various clinicopathological features as
well as survival rates were analyzed using the Fisher Exact test,
Monte Carlo test or chi- squared test. The Spearman rank cor-
relation test was used to analyze the correlation of b-catenin
and COX-2 expression with tumor grade. An association be-
tween COX-2 and b-catenin expressions was tested using the
chi-squared test. Signiﬁcant difference between b-Catenin
expression-grades in regard to high COX-2 expression scores
was identiﬁed using Z test.
Disease free survival (DFS) was calculated from the date of
diagnosis to the date of death/progression or the date of last
seen. The prognostic signiﬁcance of Cox-2 and b-catenin was
analyzed by univariate and multivariate analysis for prognos-
tic signiﬁcance for 24 months of DFS. Multivariate analysis
was carried out using the Cox proportional hazard model.
A p value of less than 0.05 was considered signiﬁcant.
3. Results
Thirty patients with colorectal carcinoma were included in the
present work. They consisted of 21 males and 9 females with
ages ranging from 32 to 70 years (mean 52 years).
Table 1 shows the clinicopathological features of the 30
patients with colorectal carcinomas studied.
Histopathologic examination of colectomy specimens re-
vealed that 26 cases were adenocarcinomas, three cases were
mucinous adenocarcinoma and one case was signet ring cell
carcinoma.
Of the 26 adenocarcinomas, 5 (16.6%) were well differenti-
ated, 14 (46.6%) were moderately differentiated, and 7
(23.33%) were poorly differentiated.
3.1. Analysis of COX-2 immunoreactivity
Normal colonic epithelium and stroma adjacent to the tumor
tissue showed no staining for COX-2 (Fig. 1A).
Table 1 clinicopathologic features of the 30 colorectal carci-
nomas cases studied.
Items Number %
Age
<50 7 23.3
>50 23 76.7
Sex
Females 9 30
Males 21 70
Site
Lt 17 56.7
Rt 13 43.3
Grade
Well 5 16.6
Moderate 14 46.6
Poor 7 23.3
Type
Adenocarcinoma 26 86.7
Mucoid carcinoma 3 10
Signet ring carcinoma 1 3.33
Stage
IIA 18 60
IIIB 12 40
LNs
+ve 12 40
ve 18 60
214 A. Kazem et al.Immunohistochemically detectable COX-2 expression has
been reported in all 30 (100%) colorectal carcinomas analyzed.
In all positive cases, COX-2 immunoreactivity pattern was lo-
cated diffusely in the cytoplasm. Weak positivity was found in
7 cases (23.3%) (Fig. 1B). Strong positivity with perinuclear
accentuation (Fig. 1C) or granular cytoplasmic pattern
(Fig. 1D and E) was observed in 23 cases (76.6%). COX-2
expression in tumourous areas was reported both in the neo-
plastic epithelial cells, as well as in the surrounding inﬂamma-
tory cells, vascular endothelial cells, smooth muscle ﬁbers,
nerve ﬁbers and ﬁbroblasts (Fig. 1C–H). Two cases of mucin-
ous adenocarcinoma showed strong positivity and one case
showed weak positivity (Fig. 1H). On the other hand the case
of signet ring cell carcinoma showed weak COX-2 positivity.
3.2. Analysis of b-catenin immunoreactivity
In normal tissue adjacent to colorectal carcinoma, b-catenin
was mainly localized in the plasma membrane of the cell-to-cell
border with a weak expression in the cytoplasm of both the
colonic epithelium and goblet cells. No nuclear b-catenin was
seen in the normal colonic mucosa (Fig. 2A).
In colorectal carcinoma tissue, b-catenin immunoreactivity
was detected in all 30 samples. Complete loss of b-catenin
immunoreactivity in the cell-to-cell border was observed in
12 cases (Fig. 2B). b-Catenin immunostaining reactivity of
grade II was observed in 18 cases (60%) (Fig. 2C). Grade III
b-catenin immunoreactivity in both the cytoplasm and nuclei
of tumor cells was seen in 12 cases (40%) (Fig. 2D). Inﬂamma-
tory cells, stromal cells, nerve ﬁbers and endothelial cells
all were b-catenin negative (Fig. 2A–E). The three cases ofmucinous adenocarcinoma showed grade II b-catenin immu-
nostaining, whereas the case of signet ring cell carcinoma
showed grade III positivity (Fig. 2F).3.2.1. Statistical analysis
The relation between both COX-2 and b-catenin expression
and various clinicopathological parameters is summarized in
Table 2.
A signiﬁcant increase in number of cases having stronger
COX-2 and b-catenin positivity was found in higher histologic
grades of colorectal carcinoma (p= 0.026 and 0.032, respec-
tively). However no signiﬁcant relation was found between
COX-2 scores and other clinicopathological parameters, includ-
ing, depth of invasion, lymph node metastasis, or tumor stage.
Grade III b-catenin expression was signiﬁcantly more frequent
in male patients (p= 0.004), Lt sided tumors (p= 0.002), high-
er histologic grade (p= 0.032) and stage (p= 0.002) tumors as
well as in node positive tumors (p= 0.002).
A signiﬁcant correlation was found between both COX-2
and b-catenin expression on one hand and histologic grade
on the other hand (p= 0.013 and 0.014, respectively).
COX-2 expression was signiﬁcantly associated with b-cate-
nin expression (v2 test = 5, p= 0.05). All Grade III b-catenin
immunostaining were strongly positive for COX-2 and all
weakly positive cases for COX-2 had grade II immunostaining
for b-catenin. b-Catenin grade III positive tumors showed a
signiﬁcantly higher frequency of strong positive expression of
COX-2 (scores > 4) than did b-catenin grade II positive
tumors (100% vs. 66.6%, Z= 2.24, P= 0.05).3.2.2. Prognosis in relation to immunostaining results
The follow-up time was 24 months after surgery.
Disease free survival and COX-2 expression; weakly versus
strongly positive (Fig. 3):
Survival analysis for all patients showed that COX-2
expression was associated with disease free survival; i.e., short-
er disease free survival was identiﬁed in patients with strong
COX-2 expression scores (p< 0.002).
Fig. 3 DFS curves according to COX-2 expression scores.
The higher the score of COX-2 immunohistochemical
expression, the lower the percentage of DFS.
Disease free survival and b-catenin expression; Grade II
versus Grade III (Fig. 4):
Survival analysis for all patients showed that b-catenin
expression was associated with disease free survival; where
shorter disease free survival was noted in patients with b-cate-
nin grade III scores (p< 0.005).
Fig. 4 DFS curves according to b-catenin expression
grades.
The higher b-catenin grade of immunostaining, the lower
the percentage of disease free survival.
Table 3 shows the relation between COX-2 and b-catenin
expression and patient’s outcome by the end of follow up per-
iod of 24 months.
Both COX-2 and b-catenin expressions were related to dis-
ease free survival with signiﬁcantly higher rates of recurrence
and death in the patients with strong COX-2 and grade III
b-catenin expression (p< 0.006 and 0.001, respectively).
Univariate analysis showed a highly signiﬁcant difference
in DFS between weak and strong COX-2 expression and also
Figure 1 Immunohistochemical staining for COX-2 (X400). (A) Absent COX-2 staining in normal colonic tissue adjacent to tumorous
area. (B) Well differentiated adenocarcinoma showing weak cytoplasmic positivity. (C) Moderately differentiated adenocarcinoma
showing strong, perinuclear cytoplasmic immunoreactivity. (D) Moderately differentiated adenocarcinoma with strong granular
cytoplasmic positivity, note positive staining of luminal inﬂammatory cells and stromal cells. (E) Strong positivity in a case of poorly
differentiated adenocarcinoma. (F) Perineural invasion with positivity of tumor cells, stromal and neural cells. (G) Positive
immunostaining of smooth muscle ﬁbers and stromal cells surrounding the tumor tissue. (H) Strong positivity in a case of mucinous
adenocarcinoma. Note positive staining of endothelial cells.
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However the statistical signiﬁcance in univariate analysis could
not be conﬁrmed through multivariate analysis (p= 0.390 and
0.129, respectively) (Table 4).
4. Discussion
Carcinogenesis and development of colorectal cancer are mul-
ti-step and multi-stage processes involving cumulative effects
of many genes and epigenetic alterations (e.g., DNA
hypomethylation).24
In this work the expression of both COX-2 and b-catenin
was studied in 30 patients with colorectal carcinoma byimmunohistochemistry. Their expression was correlated with
various clinicopathologic parameters and with patient’s
disease free survival after a follow up period of 24 months.
Evidence suggests that NSAIDs reduce the risk of CRC and
that this effect is mediated through COX-2 inhibition.5,10
COX-2 has fatty acid oxygenase activity for the synthesis of
prostaglandins from arachidonic acid. Previous studies have
reported that prostaglandin production is generally enhanced
in cancer cells, and that prostaglandins promote the prolifera-
tion and metastasis of cancer cells. Thus, COX-2 induction has
the potential to promote tumor growth and progression.25
Several studies have shown that the COX-2 expression is
elevated in colorectal cancer when compared with normal
Figure 2 Immunostaining with b-catenin monoclonal antibody (X400). (A) Membranous and cytoplasmic staining of normal colonic
glandular epithelium adjacent to tumor tissue. (B) Well differentiated colonic adenocarcinoma showing grade II positivity. (C) Grade II
positivity in a moderately differentiated colonic adenocarcinoma with retained membranous positivity in addition to the cytoplasmic
staining. (D) Poorly differentiated colonic adenocarcinoma showing grade III positivity in both the cytoplasm and nuclei of tumor tissue.
(E) Perineural invasion with grade II positivity in tumor tissue, while stromal, neural and inﬂammatory cells appear negative. (F) Grade II
positivity with weak nuclear staining in colonic mucinous adenocarcinoma.
216 A. Kazem et al.mucosa.26,27 Our results conﬁrmed these previous observations
where, COX-2 protein was detected in all of colorectal carcino-
mas – with different scores of positivity – and was absent in the
adjacent normal colorectal tissue. In the literature, increased
COX-2 expression was detected in other tumors, and was be-
lieved to be involved in their pathogenesis.28–32 Therefore
our results suggest that increased expression of COX-2 protein
correlates with colorectal carcinogenesis.
In agreement with others,25 no signiﬁcant correlation was
found in this work, between COX-2 expression scores and
many clinicopathological parameters, including gender, age,
tumor localization, depth of tumor invasion, lymph node
metastasis, or stage. However, we did ﬁnd a signiﬁcant nega-
tive correlation between the expression of COX-2 and the
degree of tumor differentiation (p= 0.026). Others reported
that COX-2 expression is related to lymph node involvement
and Duke’s stage.32 These discrepancies may be related to
the use in this study of the TNM staging system or to the dif-
ferent scoring systems and antibodies employed in
immunohistochemistry.
In line with previous publications;33 we did ﬁnd in this
study a strong positivity of stromal cells of the tumorous areas
to COX-2 in contrast to their complete negativity in the nor-
mal adjacent mucosa. This important ﬁnding suggests thatCOX-2 might be a mediator of tumor epithelial-stromal inter-
actions in colorectal carcinoma. Therefore it could be possible
to eliminate the growth and invasive progression promoting ef-
fects of stromal ﬁbroblasts by the use of NSAIDs especially
COX-2 inhibitors for treatment and prevention of colorectal
carcinoma.
It has been demonstrated that COX-2 is one of several
genes that are transcriptionally activated by b-catenin.34
In this study, b-catenin localization was different in cancer
cells and normal mucosal cells. Normal colonic epithelial cells
showed strong uniform membranous b-catenin immunostain-
ing at the cell–cell junction. The localization of b-catenin
immunoreactivity to the plasma membrane and cell to cell
border of the normal colonic mucosa is consistent with the
ﬁndings of Iwamoto et al.35 where they stated that the
cytoplasmic tail of b-catenin binds to E-cadherin and, indi-
rectly, to the cytoskeleton, so it is localized to the adherens’
junction of the cell-to-cell plasma membrane. Formation of
multiprotein complexes consisting of proteins such as APC,
axin and b-catenin makes b-catenin a target for degradation,
so that no cytoplasmic or nuclear b-catenin will be detected
in normal tissue.36 Other workers,37,38 stated that localization
of b-catenin, primarily to the apical-lateral cell membrane,
signiﬁes its role in cell adhesion.
Table 2 Relation of COX-2 and b-catenin expression with various clinicopathologic parameters studied.
COX-2 b-Catenin
Weak Strong II III
No. % No. % No. % No. %
Age
<50 0 0.0 7 100.0 2 28.57 5 71.42
>50 7 30.4 16 69.56 16 69.56 7 30.43
FEp 0.154 0.084
Sex
Male 4 19.04 17 80.95 9 42.85 12 57.14
Female 3 33.3 6 66.6 9 100.0 0 0.0
FEp 0.640 0.004*
Site
Left 2 11.76 15 88.23 6 35.29 11 64.7
Right 5 38.46 8 61.53 12 92.30 1 7.6
FEp 0.190 0.002*
Grade
Well 3 60.0 2 40.0 5 100.0 0 0.0
Moderate 2 14.28 12 85.71 8 57.14 6 42.85
Poor 0 0.0 7 100.0 2 28.57 5 71.42
MCp 0.026* 0.032*
Mucoid 1 33.3 2 66.6 3 100.0 0 0.0
Signet 1 100.0 0 0.0 0 0.0 1 100.0
Stage
IIA 6 33.3 12 66.6 15 83.33 3 16.66
IIIB 1 8.33 11 91.66 3 25.0 9 75.0
FEp 0.193 0.002*
LNs
N1+ 2 1 8.3 11 91.66 3 25.0 9 75.0
No 6 33.3 12 66.6 15 83.33 3 16.66
FEp 0.193 0.002*
FEp: p value for Fisher exact test.
MCp: p value for Monte Carlo test.
* Statistically signiﬁcant at p 6 0.05.
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Figure 3 COX-2 expression curve in relation to disease free
survival (24 months).
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Figure 4 b-Catenin expression curve in relation to disease free
survival (24 months).
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primary colorectal carcinomas studied (maintained or lost
membranous + cytoplasmic or nuclear positivity). Thisaberrant distribution of b-catenin inferred from cytoplasmic
or nuclear distribution which was sometimes also cell–cell
adhesion-deﬁcient reﬂects either an ineffective b-catenin or
Table 3 Relation between COX-2 and b-catenin and patient’s outcome at the end of 24 months.
Survival COX-2 b-Catenin
Weak Strong II III
No % No % No % No %
End of 24 months
Deaths 1 14.28 9 39.13 0 0.0 10 83.3
Recurrence 0 0.0 10 43.4 8 44.4 2 16.66
Free 6 85.71 4 17.39 10 55.5 0 0.0
MCp 0.006* <0.001*
FEp: p value for Fisher Exact test.
MCp: p value for Monte Carlo test.
* Statistically signiﬁcant at p 6 0.05.
Table 4 Univariate and multivariate analysis of clinicopathologic parameters and COX-2 and b-catenin status as predictors of DFS
in colorectal carcinoma patients.
Variables Univariate analysis Multivariate analysis
Test P value Test P value
Age t 0.918 –
Sex FE 0.194 –
Site FE 0.103 –
Grade MW 0.001* Cox regression 0.231
TNM Stage MW 0.008* 0.084
COX-2 FE 0.002* 0.390
b-catenin FE 0.002* 0.129
Variables were subgrouped as follows: Age 650 years compared with >50 years: site Lt vs. Rt: Grades I–II compared with grade III: Stage IIA
vs. IIIB, COX-2 weak versus strong: b-catenin grade II expression versus grade III. LNs involved were not added to the parameters studied
being included in the TNM stage.
Only variables with p< 0.05 in univariate analysis were included in the multivariate analysis.
FE: Fisher Exact test. t= Student t-test. MW: Mann Whitney test.
* Statistically signiﬁcant at p 6 0.05.
218 A. Kazem et al.loss of b-catenin connection to the cytoskeleton. Observations
that are documented in other reports,39 where they thought
that an abnormally high amount of b-catenin in the cytoplasm
and not in the intercellular boundary seems to indicate a
b-catenin protein with oncogenic potential. This cytoplasmic
and nuclear accumulations of b-catenin suggest enhanced
transcription and activation of the target genes (such as
c-myc, cyclin D1 and matrilysin) which are responsible for
tumor proliferation and malignant progression through
interaction with members of the TCF/LEF DNA-binding
family.40,41
In agreement with other workers42 we reported a higher
expression of b-catenin in males (p= 0.004). On the other
hand we did not ﬁnd any correlation between b-catenin expres-
sion and patient’s age. A signiﬁcant association between Lt
sided tumors and stronger b-catenin expression was noted in
our study (p= 0.002) a ﬁnding previously reported by
others.43
Grade III expression of b-catenin that we observed corre-
lated signiﬁcantly with deteriorating tumor grade
[p= 0.032], ﬁndings that are supported by other publica-
tions.44 However others42 reported lower expression of b-cate-
nin in high grade tumors. These discrepancies could be due tothe use in our study of a different b-catenin scoring system of
immunostaining. Furthermore, a signiﬁcant association be-
tween grade III b-catenin expression in colorectal carcinomas,
and advanced tumor stage (depth of invasion) was noted
[p< 0.002]. Where, the more deeply invasive tumors (IIIB)
showed higher grade expression of b-catenin than superﬁcial
tumors (IIA). Similar ﬁndings have been reported previously
both in CRC and in other types of human carcinoma.42,16 In
the present series also and in agreement with others,34 high
grade expression of b-catenin was associated with lymph node
metastasis [p= 0.002].
In line with our results some workers.45 recommended the
use of b-catenin as a marker of colorectal tumor progression
and explained it by loss of b-catenin-mediated cell–cell adhe-
sion, and polarity and activation of genes necessary for inva-
sion and dissociation.
A positive association between the COX-2 and b-catenin
was observed in the current work (p< 0.05). Furthermore,
b-catenin grade III positive tumors showed a signiﬁcantly
higher frequency of strongly COX-2 positive tumors than did
b-catenin grade II positive tumors (P= 0.05). In addition
their expressions were correlated with higher colorectal adeno-
carcinoma grade. These relationships are supported by another
Prognostic signiﬁcance of COX-2 and b-catenin in colorectal carcinoma 219study43 who stated that colonic adenocarcinoma is character-
ized by correlated cellular expression of COX-2 and b-catenin
and that a neoplastic COX-2/b-catenin positive phenotype
may be linked to colorectal cancer progression. The PGE2,
produced by COX-2, rapidly causes transactivation of EGFR,
which triggered the ERK2-mitogenic signaling pathway in a
colon cancer cell line.46 Furthermore, PGE2 increases the inva-
siveness of colon cancer cells by trans-activating c-Met and
increasing the tyrosine phosphorylation of b-catenin.47 A re-
cent study has also shown that b-catenin stabilizes COX-2
mRNA by interacting with AU-rich elements in a 3 V untrans-
lated region.48 Others49 concluded that the pCOX2-0.8 mini-
mal promoter contains a novel functional T-cell factor/
lymphoid enhancer factor (TCF/LEF)-response element
(TBE Site II; -689/-684) that responds directly to enhanced
Wnt/b-catenin signaling and which may be important for the
onset/progression of gastric cancer. Considering these data,
it may be possible that COX-2 and b-catenin may form a po-
sitive feedback loop.
In agreement with others42,50–52 a strong COX-2 and grade
III b-catenin expression were associated with shorter disease
free survival (p< 0.002 and 0.001, respectively); where pa-
tients with higher scores of expression had poorer disease free
survival at the end of a follow up period of 24 months. Both
COX-2 and b-catenin expression were related to patient’s dis-
ease free survival in the present study. A signiﬁcantly lower fre-
quency of disease free survivors was noted among patients
having strong COX-2 and grade III b-catenin expression
(p< 0.006 and 0.001, respectively). Furthermore, in univariate
analysis patients with a strong COX-2 expression and grade III
have a shorter DFS than those with weak COX-2 and grade II
b-catenin expression (p= 0.002). However this signiﬁcance
could not be maintained in multivariate analysis. This
means either that they are not independent poor prognostic
factors or it might simply be due to the restricted number of
patients in our study (30 cases).5. Conclusion
From the present work, it can be concluded that, the detection
of diffuse COX-2 cytoplasmic expression only in colorectal
carcinoma and increased expression scores in higher tumor
grades implicate that COX-2 might be an early marker of neo-
plastic transformation involved in both initiation and progres-
sion of colorectal carcinoma.
The alterations in the expression and cellular localization of
b-catenin occurs early in colorectal tumorigenesis and becomes
more strongly expressed in high-grade, deeply invasive and
lymph node metastatic tumors suggesting that b-catenin
expression may add prognostic information to standard
clinicopathological parameters that can be used in selecting
candidates for closer follow up and aggressive adjuvant
therapy.
In our present study, COX-2 showed signiﬁcant association
with the expression of b-catenin in colorectal carcinoma, sug-
gesting a coordinated local interaction between these mole-
cules to potentiate the growth and invasion of colorectal
carcinoma. Therefore they could be used to select patients that
might beneﬁt from new pharmacological agents and gene ther-
apy targeting both prostaglandin and b-catenin mediated
growth pathways.At present, whether COX-2 and b-catenin expressions are a
valid prognostic marker for colorectal carcinoma remains con-
troversial. Their relation to DFS was signiﬁcant only in uni-
variate but not multivariate analysis. So they might have the
potential to be a poor predictor of prognosis. To elucidate this
relationship, further investigations are required on a larger
number of cases.
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